Anti-DLL3 antibody drug conjugates and methods of use
US9133271B1 · kind B1 · utility
8Cited by
46References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2015 |
| Grant date | Sep 15, 2015 |
| Priority date | — |
| Expiry date | Jun 17, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provide are novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat recurrent tumors and to reduce or inhibit tumor recurrence in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.